(2026). Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study. Open Access Journal of Urology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study."
Open Access Journal of Urology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study."
Open Access Journal of Urology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.